Literature DB >> 1971302

An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.

J C Yang1, D Perry-Lalley, S A Rosenberg.   

Abstract

Tumor-infiltrating lymphocytes (TILs) are host T cells that can be grown from fresh murine and human tumors using interleukin-2 (IL-2) in bulk cultures. These activated T cells have been shown to have significant antitumor activity both in vitro and in vivo. A technique is described for the separation of Thy-1.2-positive TILs from fresh murine tumors using antibody-coated magnetic beads, permitting the examination of growth conditions for these cells. TILs with increased therapeutic efficacy are obtained from the immunogenic MCA 38 and MCA 105 tumors when culture conditions employing low levels of IL-2 (10 vs. 1,000 U/ml) and irradiated autologous tumor restimulation are used. TILs grown under these conditions can mediate a 93% reduction of 3-day-old established pulmonary metastases when as few as 2.5 x 10(5) cells are adoptively transferred with systemic IL-2. These culture conditions are utilized to grow TILs from the nonimmunogenic MCA 102 tumor for which bulk TIL culture methods are unsuccessful. MCA 102 TILs grown in this fashion demonstrate in vivo therapeutic efficacy against established autologous pulmonary metastases.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971302

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN: 0732-6580


  11 in total

1.  Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells.

Authors:  C J Bartels; S A Rosenberg; J C Yang
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

2.  Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.

Authors:  D J Cole; J K Taubenberger; B A Pockaj; J R Yannelli; C Carter; J Carrasquillo; S Leitman; S M Steinberg; S A Rosenberg; Y C Yang
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

3.  Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

Authors:  N P Restifo; F Esquivel; A L Asher; H Stötter; R J Barth; J R Bennink; J J Mulé; J W Yewdell; S A Rosenberg
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422

4.  Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.

Authors:  F Arienti; F Belli; L Rivoltini; C Gambacorti-Passerini; L Furlan; L Mascheroni; A Prada; M Rizzi; E Marchesi; M Vaglini
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

5.  Effect of allogeneic tumor cells, interleukin-2 and interleukin-6, on the growth of subcutaneous syngeneic tumors.

Authors:  A Eisenthal; Y Skornick; O Merimsky; R Hirsch; V Zakut; I Ron; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

6.  Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.

Authors:  M Laude; K L Russo; M B Mokyr; S Dray
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

7.  Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.

Authors:  F M Marincola; S Ettinghausen; P A Cohen; L B Cheshire; N P Restifo; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

8.  Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.

Authors:  S E Karp; A Farber; J C Salo; P Hwu; G Jaffe; A L Asher; E Shiloni; N P Restifo; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

9.  Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.

Authors:  S Théoleyre; K Mori; B Cherrier; N Passuti; F Gouin; F Rédini; D Heymann
Journal:  BMC Cancer       Date:  2005-09-27       Impact factor: 4.430

10.  Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes.

Authors:  R J Barth; J J Mulé; P J Spiess; S A Rosenberg
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.